At a glance
- Recommended action
- Confirm product coverage and HTS classifications, model duty exposure, and review FTZ, origin, and mitigation options before the applicable effective date.
- Effective date
- July 31, 2026 (Annex III companies); September 29, 2026 (other affected importers)
- What changed
- Proclamation 11020 adds Section 232 tariffs on certain patented pharmaceuticals and pharmaceutical ingredients, with company-specific and broader effective dates.
- Who is affected
- Importers of patented pharmaceuticals, APIs, and key starting materials, including FTZ operators and companies relying on preference programs.
- Business impact
- Duty rates can reach up to 100% depending on product type, origin, and program participation, with reporting obligations beginning on the first effective date.
Recommended actions
What importers should do next
- Identify whether imported products are patented pharmaceuticals or associated pharmaceutical ingredients.
- Confirm whether products qualify as generic pharmaceuticals.
- Evaluate country-of-origin impacts on applicable tariff treatment.
- Review product eligibility for available exclusions and exemptions.
- Assess whether existing or planned U.S. manufacturing investments may qualify for reduced tariff treatment.
- Review drawback opportunities to recover duties.
- Evaluate FTZ procedures and Privileged Foreign Status requirements.
- Monitor Commerce Department and CBP guidance for additional implementation requirements.
Key takeaway
Section 232 pharmaceutical tariffs create staggered compliance deadlines and potentially severe duty exposure—importers must confirm coverage, reporting obligations, and mitigation options before July 31 and September 29, 2026.
The United States has implemented new Section 232 tariff measures on certain imported patented pharmaceuticals and pharmaceutical ingredients, citing national security concerns related to pharmaceutical supply chain dependency and domestic manufacturing capacity.
The new measures establish tariff rates based on product type, country of origin, and eligibility for approved domestic manufacturing commitments.
On April 2, 2026, the President issued Proclamation 11020, imposing additional duties on certain imports of patented pharmaceuticals and patented pharmaceutical ingredients, including active pharmaceutical ingredients (APIs) and key starting materials.
The measures take effect:
- July 31, 2026 for products of companies specifically identified in Annex III of the Proclamation.
- September 29, 2026 for products of all other companies.
Beginning July 31, 2026, importers of affected pharmaceutical products are required to comply with CBP reporting requirements associated with the new Section 232 pharmaceutical tariff program, even during periods where no additional duties may yet be payable.
The Section 232 pharmaceutical program establishes different tariff outcomes depending on the origin of the merchandise and the manufacturer's participation in approved U.S. government programs.
Covered patented pharmaceuticals and associated pharmaceutical ingredients are generally subject to a tariff rate that may reach 100% ad valorem.
European and Asian Strategic Trading Partners: A reduced tariff rate applies to products originating from: European Union member states, Japan, South Korea, Switzerland, and Liechtenstein. These products are generally subject to a 15% tariff rate, unless a lower rate applies under another provision of the proclamation.
United Kingdom: Products originating from the United Kingdom are excluded from tariffs.
Companies with Approved Onshoring Plans: Manufacturers with Commerce-approved plans to increase pharmaceutical production in the United States may qualify for a significantly reduced tariff rate. The reduced rate is intended to encourage pharmaceutical manufacturing investment and supply chain localization within the United States.
Companies with Onshoring and MFN Pricing Agreements: Certain companies that have both approved domestic manufacturing commitments, and Most-Favored-Nation (MFN) pharmaceutical pricing agreements with the U.S. Government may qualify for temporary zero-duty treatment through January 20, 2029.
Several categories of pharmaceutical products may qualify for duty-free treatment under the proclamation, including orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, animal health pharmaceuticals. Eligibility for these exemptions depends on criteria established by the Department of Commerce and other federal agencies.
The proclamation specifically excludes generic pharmaceutical products and generic pharmaceutical ingredients from the current Section 232 tariff action.
Free Trade Agreements and Preference Programs
Eligibility for preferential treatment under U.S. free trade agreements or trade preference programs does not eliminate the application of these Section 232 tariffs where applicable.
The proclamation contains important implications for Foreign-Trade Zone operations.
Affected pharmaceutical products admitted into a U.S. FTZ on or after the effective date generally must be admitted in Privileged Foreign Status.
Sources
Authority references
- Presidential Proclamation 11020 - White House - 2026-04-02
- U.S. Customs and Border Protection - CBP - 2026
Need help understanding your exposure?
Crane Trade Consulting can help assess tariff impacts, validate exclusions and develop practical mitigation strategies.